-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 18, Buchang Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Tonghua Guhong's concentrated solution of levetiracetam for injection and Baoding Tianhao's apixaban tablets were approved for listing
.
Levetiracetam injection concentrated solution and apixaban tablets have been included in the third batch of centralized procurement, but there are still many companies that have been approved or applied for listing
Levetiracetam injection concentrated solution is an anti-epileptic drug, mainly used for the treatment of partial seizures (with or without secondary generalized seizures) in adults and children over 4 years of age with epilepsy.
Oral preparations cannot be used temporarily in patients Time can replace administration
.
Levetiracetam is a large variety of 1 billion yuan in China.
Due to the late launch of the injection form, the market is still in its infancy
.
According to data from Meinenet, the sales of terminal levetiracetam injections in 2021H1 China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 40 million yuan, a year-on-year increase of 50.
Sales of terminal levetiracetam injections in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
Up to now, there are 13 domestic manufacturers of concentrated solution of levetiracetam for injection, and 12 companies have passed the consistency evaluation
.
6 companies including Huiyu Pharmaceutical, Huahai Pharmaceutical, and Northeast Pharmaceutical are under review for the product listing application
Apixaban tablets are anticoagulant factor Xa inhibitors, mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE)
.
Apixaban tablets have been included in the third batch of centralized procurement.
Sales of apixaban in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
The latest data shows that due to the impact of centralized procurement, the terminal sales of apixaban in China's public medical institutions in 2021H1 fell sharply by 54.
It is worth noting that there are 14 companies whose applications for Apixaban tablets are under review, including Yangzijiang Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, and Changzhou Pharmaceutical Factory
Data source: Mi Nei.
